Expanding HIV Prevention Choices: What’s on the Horizon?
Craig W. Hendrix, MD
Wellcome Professor and Director, Division of Clinical Pharmacology
Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2019. All rights reserved.
Craig Hendrix is the Wellcome Professor and Director, Division of Clinical Pharmacology, at Johns Hopkins University School of Medicine. He trained in infectious diseases and clinical pharmacology at Hopkins before 10 years as an Air Force physician and 22 years at Johns Hopkins. Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis. Among other research projects, he’s involved as Principal Investigator or Project Leader in a variety of early phase topical PrEP program project grants funded by NIH. He also serves as director of the Pharmacology Group for both the Microbicide Trials Network and HIV Prevention Trials Network. In 2018, he was recognized by ACCP with the Distinguished Investigator Award.
At the completion of this educational session, learners will:
- Describe the value of CHOICE among HIV prevention platforms.
- Identify special population concerns with oral PrEP, including transgender women and pregnant women.
- Discuss ongoing development of topical microbicides, including vaginal and rectal microbicides.
- Discuss ongoing development of long-acting PrEP, including antiretrovirals and monoclonal antibodies.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
